Global, regional, and national burden of blindness and vision loss attributable to high fasting plasma glucose from 1990 to 2019, and forecasts to 2030: A systematic analysis for the Global Burden of Disease Study 2019

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes/Metabolism Research and Reviews Pub Date : 2024-04-18 DOI:10.1002/dmrr.3802

Cong Li, Guangyao Hua, Shunming Liu, Honghua Yu, Xiaohong Yang, Lei Liu

{"title":"Global, regional, and national burden of blindness and vision loss attributable to high fasting plasma glucose from 1990 to 2019, and forecasts to 2030: A systematic analysis for the Global Burden of Disease Study 2019","authors":"Cong Li, Guangyao Hua, Shunming Liu, Honghua Yu, Xiaohong Yang, Lei Liu","doi":"10.1002/dmrr.3802","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>To systematically clarify the spatiotemporal trends, and age-sex-specific blindness and vision loss (BVL) burden due to high fasting plasma glucose (HFPG) from 1990 to 2019, and project this burden over the next decade.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We obtained the number and rate of years lived with disability (YLDs) for the BVL burden attributable to HFPG by age, sex, socio-demographic index (SDI), and location between 1990 and 2019 from the Global Burden of Disease (GBD) 2019 database. The average annual percentage changes (AAPCs) were calculated to assess the temporal trends of HFPG-attributable BVL burden. The Bayesian age-period-cohort model was used to predict the HFPG-attributable BVL burden.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2019, the global number and age-standardized rate (ASR) for YLDs of BVL attributable to HFPG were 673.13 (95% UI: 159.52 to 1565.34) thousand and 8.44 (95% UI: 2.00 to 19.63) per 100,000 people, respectively. The highest burdens were found in Oceania, South Asia, and Southeast Asia, and the BVL burden due to HFPG was higher in the elderly and lower SDI regions. From 1990 to 2019, the global ASR of HFPG-attributable BVL gradually increased with AAPC (95% CI) being 0.80 (0.74 to 0.86). In addition, the HFPG-attributable BVL burden will slightly increase in the future decade.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The HFPG remains the important cause of BVL worldwide, placing a substantial disease burden. From 1990 to 2019, the age-standardized burden of BVL due to HFPG increased, and will consistently increase in the future decade, particularly in the elderly and in regions with middle SDI or below.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"40 4","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.3802","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3802","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To systematically clarify the spatiotemporal trends, and age-sex-specific blindness and vision loss (BVL) burden due to high fasting plasma glucose (HFPG) from 1990 to 2019, and project this burden over the next decade.

Materials and Methods

We obtained the number and rate of years lived with disability (YLDs) for the BVL burden attributable to HFPG by age, sex, socio-demographic index (SDI), and location between 1990 and 2019 from the Global Burden of Disease (GBD) 2019 database. The average annual percentage changes (AAPCs) were calculated to assess the temporal trends of HFPG-attributable BVL burden. The Bayesian age-period-cohort model was used to predict the HFPG-attributable BVL burden.

Results

In 2019, the global number and age-standardized rate (ASR) for YLDs of BVL attributable to HFPG were 673.13 (95% UI: 159.52 to 1565.34) thousand and 8.44 (95% UI: 2.00 to 19.63) per 100,000 people, respectively. The highest burdens were found in Oceania, South Asia, and Southeast Asia, and the BVL burden due to HFPG was higher in the elderly and lower SDI regions. From 1990 to 2019, the global ASR of HFPG-attributable BVL gradually increased with AAPC (95% CI) being 0.80 (0.74 to 0.86). In addition, the HFPG-attributable BVL burden will slightly increase in the future decade.

Conclusions

The HFPG remains the important cause of BVL worldwide, placing a substantial disease burden. From 1990 to 2019, the age-standardized burden of BVL due to HFPG increased, and will consistently increase in the future decade, particularly in the elderly and in regions with middle SDI or below.

Abstract Image

查看原文本刊更多论文

1990 年至 2019 年全球、地区和国家因空腹血浆葡萄糖过高导致失明和视力丧失的负担，以及对 2030 年的预测：2019 年全球疾病负担研究的系统分析

目的系统地阐明 1990 年至 2019 年期间空腹血浆葡萄糖过高（HFPG）导致失明和视力丧失（BVL）的时空趋势和特定年龄-性别负担，并预测未来十年的负担情况。材料与方法我们从全球疾病负担（GBD）2019 数据库中获得了 1990 年至 2019 年期间因高空腹血浆葡萄糖而导致的残疾生活年数（YLD）的数量和比率，并按年龄、性别、社会人口指数（SDI）和地点进行了分类。通过计算年均百分比变化（AAPCs）来评估高频气胸归因于BVL负担的时间趋势。贝叶斯年龄-时期-队列模型用于预测高危人群可归因的BVL负担。结果 2019年，HFPG所致BVL的全球YLD数量和年龄标准化率（ASR）分别为每10万人673.13（95% UI：159.52至1565.34）千例和8.44（95% UI：2.00至19.63）例。大洋洲、南亚和东南亚的负担最高，老年人和SDI较低的地区因HFPG导致的BVL负担较高。从 1990 年到 2019 年，全球 HFPG 可归因于 BVL 的 ASR 逐渐增加，AAPC（95% CI）为 0.80（0.74 至 0.86）。此外，在未来十年中，HFPG 导致的 BVL 负担将略有增加。结论 HFPG 仍是全球 BVL 的重要病因，造成了巨大的疾病负担。从 1990 年到 2019 年，HFPG 导致的 BVL 年龄标准化负担有所增加，并将在未来十年持续增加，尤其是在老年人和 SDI 中等或以下的地区。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢

CiteScore

17.20

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.